Cargando…

Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma

Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse mus...

Descripción completa

Detalles Bibliográficos
Autores principales: Slot-Steenks, Mathilde M. Bruins, Hamdy, Neveen A.T., van de Sande, Michiel A.J., Vriens, Dennis, Cleven, Arjen H.G., Appelman-Dijkstra, Natasha M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107201/
https://www.ncbi.nlm.nih.gov/pubmed/27709474
http://dx.doi.org/10.1007/s12020-016-1092-5
_version_ 1782467174420447232
author Slot-Steenks, Mathilde M. Bruins
Hamdy, Neveen A.T.
van de Sande, Michiel A.J.
Vriens, Dennis
Cleven, Arjen H.G.
Appelman-Dijkstra, Natasha M.
author_facet Slot-Steenks, Mathilde M. Bruins
Hamdy, Neveen A.T.
van de Sande, Michiel A.J.
Vriens, Dennis
Cleven, Arjen H.G.
Appelman-Dijkstra, Natasha M.
author_sort Slot-Steenks, Mathilde M. Bruins
collection PubMed
description Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse muscle weakness and pain, generalized bone pains and multiple insufficiency fractures of heels, ankles and hips due to a hypophosphatemic osteomalacia. A fibroblast growth factor 23-producing phosphaturic mesenchymal tumor localized in the left quadriceps femoris muscle was identified 7 years after onset of symptoms. Excision of the tumor resulted in normalization of serum phosphate and fibroblast growth factor 23 levels and in complete resolution of the clinical picture with disappearance of all musculoskeletal symptoms. This case illustrates the diagnostic difficulties in establishing a diagnosis tumor-induced osteomalacia and in identifying the responsible tumor. Our case underscores the clinical need to investigate all patients with persistent musculoskeletal symptoms for hypophosphatemia. A systematic approach is of pivotal importance because early recognition and treatment of the metabolic abnormality can prevent deleterious effects of osteomalacia on the skeleton.
format Online
Article
Text
id pubmed-5107201
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-51072012016-11-29 Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma Slot-Steenks, Mathilde M. Bruins Hamdy, Neveen A.T. van de Sande, Michiel A.J. Vriens, Dennis Cleven, Arjen H.G. Appelman-Dijkstra, Natasha M. Endocrine Clinical Management of Endocrine Diseases Tumor-induced osteomalacia is a rare acquired metabolic bone disorder characterized by isolated renal phosphate wasting due to abnormal tumor production of fibroblast growth factor 23. We report the case of a 59 year old woman referred to our department with a long history of progressive diffuse muscle weakness and pain, generalized bone pains and multiple insufficiency fractures of heels, ankles and hips due to a hypophosphatemic osteomalacia. A fibroblast growth factor 23-producing phosphaturic mesenchymal tumor localized in the left quadriceps femoris muscle was identified 7 years after onset of symptoms. Excision of the tumor resulted in normalization of serum phosphate and fibroblast growth factor 23 levels and in complete resolution of the clinical picture with disappearance of all musculoskeletal symptoms. This case illustrates the diagnostic difficulties in establishing a diagnosis tumor-induced osteomalacia and in identifying the responsible tumor. Our case underscores the clinical need to investigate all patients with persistent musculoskeletal symptoms for hypophosphatemia. A systematic approach is of pivotal importance because early recognition and treatment of the metabolic abnormality can prevent deleterious effects of osteomalacia on the skeleton. Springer US 2016-10-05 2016 /pmc/articles/PMC5107201/ /pubmed/27709474 http://dx.doi.org/10.1007/s12020-016-1092-5 Text en © The Author(s) 2016 This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Clinical Management of Endocrine Diseases
Slot-Steenks, Mathilde M. Bruins
Hamdy, Neveen A.T.
van de Sande, Michiel A.J.
Vriens, Dennis
Cleven, Arjen H.G.
Appelman-Dijkstra, Natasha M.
Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title_full Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title_fullStr Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title_full_unstemmed Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title_short Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
title_sort identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
topic Clinical Management of Endocrine Diseases
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5107201/
https://www.ncbi.nlm.nih.gov/pubmed/27709474
http://dx.doi.org/10.1007/s12020-016-1092-5
work_keys_str_mv AT slotsteenksmathildembruins identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma
AT hamdyneveenat identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma
AT vandesandemichielaj identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma
AT vriensdennis identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma
AT clevenarjenhg identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma
AT appelmandijkstranatasham identifyingtheculpritlesionintumorinducedhypophosphatemiathesolutionofaclinicalenigma